Table 3 Changes in the variables evaluated between the baseline and three months after the second treatment cycle (n = 39 patients)

Headache days

23.8 ± 6.9*

9.2 ± 9.8*

<0.001

62%

27/39 (69.2%)

Migraine days

14.7 ± 7.6*

3.9 ± 6.4*

<0.001

73.1%

29/39 (74.3%)

Medication intake days

18.9 ± 9*

7.4 ± 8.2*

<0.001

57.7%

28/39 (71.8%)

Triptan intake days

5.4 ± 7.3*

2.3 ± 3.7*

<0.001

36.3%

11/19 (57.9%)